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ABSTRACT
Background: ANCA associated vasculitides (AAV) often present with a chronic 
relapsing course. Relapse leads to increased immunosuppressive exposure and 
consequent toxicity. While two randomized controlled trials have shown rituximab 
(RTX) to be the most effective induction treatment in patients with relapsing disease, 
the optimal treatment duration and RTX dose remain debated. Whether to administer 
a maintenance dose to every patient, at a fixed time interval or on the basis of B cell 
count and ANCA titre or only when disease manifestations do occur is still debated 
as well.
Methods: 11 patients (5 with granulomatosis with polyangiitis, 4 with microscopic 
polyangiitis-MPA-, and 2 with eosinophilic granulomatosis with polyangiitis -EGPA-) 
intolerant or refractory to conventional therapies including cyclophosphamide were 
enrolled. All patients received the so called “improved 4+2” RTX scheme as a rescue 
therapy. Following RTX administration, immunosuppressive drugs were rapidly 
tapered and no immunosuppressive maintenance therapy had been given. 
Results: After a mean follow-up of 85 months since the “4+2” RTX protocol: four 
out of 11 patients (37%, 1 EGPA and 3 MPA, all MPO-positive) remained in remission 
after one cycle of “4+2” RTX infusion protocol with no relapse for a median 66 
months [60-108]). Seven relapsing patients were re-treated once with RTX (again as 
monotherapy with the same protocol) after a median of 54 months (24-96). Following 
re-treatment, they again showed complete remission over a median of 32 months 
(12-96) of observation. 
Conclusion: In one of the longest-term observation (85 months) studies, 
sustained clinical remission without immunosuppressive maintenance therapy (and 
a negligible dose of prednisone since the 5thmonth) was obtained by the “4 + 2” RTX 
infusion protocol in patients with ANCA-associated vasculitis intolerant or refractory 
to conventional therapy.
INTRODUCTION
Granulomatosis with polyangiitis (GPA), 
microscopic polyangiitis (MPA), and eosinophilic 
granulomatosis with polyangiitis (EGPA) are small-vessel 
vasculitides associated with antineutrophil cytoplasm 
antibodies (ANCA) [1]. Classification has been historically 
performed according to the clinical phenotype together 
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with ANCA positivity or histological confirmation [2], 
although a recent genome-wide association (GWAS) 
study demonstrated that, from a genetic perspective, 
ANCA-associated vasculitis (AAV) are best defined 
by ANCA specificity rather than clinical features [3]. 
Disease severity ranges from mild manifestations to 
life- or organ-threatening forms. AAV are characterized, 
particularly in the proteinase 3 (PR3)-associated group [4], 
by a chronic relapsing course leading to repeat exposure 
to immunosuppression with increased adverse events and 
organ damage [5].
Rituximab (RTX), an anti-CD20 monoclonal 
antibody, is an effective induction treatment of AAV in 
both newly diagnosed and relapsing patients [6-8]. The 
efficacy of repeat dose RTX as maintenance therapy has 
been currently debated in both retrospectively [9, 10] and 
prospectively studies [10]. However, a number of issues 
remain unmet, including the number/yearly and amounts 
of repeat dose RTX, and duration of maintenance treatment 
[11]. Whether or not redosing should be given at a fixed 
time interval or driven by rising of ANCA titre and B cell 
count or symptoms, or both, remains to be established. 
Moreover, the long-term outcome after discontinuation of 
RTX treatment is still unknown. 
We have previously shown a favorable outcome of 
11 patients with refractory AAV treated with a “4+2” RTX 
protocol [12]. RTX was administered after unsuccessful 
or not tolerated cycle(s) of cyclophosphamide in 9 out 
11 patients. This“4+2” protocol (so called “improved 
protocol” [12]) had been generally well tolerated, but its 
long-term safety profile has to be demonstrated in AAV. 
We are now reporting our 10-years’ experience 
with these 11 prospectively enrolled patients. Since our 
treatment policy was not to repeat RTX administration 
unless patients showed definite signs of clinical relapse, 
our data provide some evidence that at least in non-
granulomatous or MPO-associated ANCA vasculitis, a 
maintenance therapy following the 4+2 RTX protocol is 
unneeded. 
RESULTS
The mean duration of disease and follow-up 
after “4+2” RTX protocol was 119 months (range 60-
189 months) and 85 months (range 45-132 months), 
respectively.
Long term clinical and laboratory parameters before 
and after the “4+2” RTX protocol are shown in Table 1. 
Significant decreases (baseline mean value; 3 months, 1 
year, 3 year, end of follow-up, p < 0.05) were found in the 
mean levels of ESR, ANCA, proteinuria/24h, IgG, IgM, 
and C-reactive protein. 
Mean serum creatinine values were 1.49 mg/dl (0.6-
2.4) at baseline, 1.07 (0.6-1.8) after 3 months, 1 year: 
1.06 mg/dl; 3 year: 1.2 mg/dl and 1.09 mg/dl (0.6-1.6) 
at end of follow-up. The “4+2” RTX protocol resulted 
in a significant decrease of mean BVAS (baseline: 22; 
3 months: 4; 1 year: 3; 3 year and end of follow-up: 
0). Constitutional symptoms, including arthralgia, 
weakness, and fever, disappeared in all the previously 
affected patients, while large necrotizing skin ulcers and 
polyneuropathy gradually resolved in 9 months.
All patients had complete peripheral blood-B cell 
depletion after the first “4+2” RTX protocol. The CD20+ 
B cells were detectable in the circulation after a mean of 
11.5 months (9-19 months). Of note, at 36 months, CD20 
cell number was still lower than baseline (p < 0.01).
Patients were not given any further 
immunosuppressive maintenance therapy after “4+2” RTX 
protocol, and oral prednisone was tapered to 5 mg/day by 
the end of the 3rd month after RTX.
Time free from disease after the first RTX treatment 
stratifying patients for ANCA profile is shown in Figure 1. 
We failed to retrieve any independent predictors of 
AAV relapse after multivariate analysis, probably due to 
small sample size. 
Seven out of 11 patients remained in remission for at 
least 60 months after one cycle of “4+2” RTX, and 4 did 
not experience any relapse at all, despite the absence of 
maintenance immunosuppressive therapy. Of note, all four 
out of 11 patients (37%, 1 EGPA, 3 MPA) that remained 
in remission after one cycle of “4+2” RTX protocol, with 
no relapse (median 66 months [60-108]) were MPO-
positive. In the 7 relapsing patients (4 within and 3 after 
5 years of follow-up) a second cycle of infusion of RTX 
alone was given because of worsening of clinical settings. 
Those patients showed a complete clinical response after 
the second cycle with normalization of the clinical and 
serologic profile. All 4 patients relapsing in the first 5 
years of follow-up after the “4+2” RTX cycle were PR3 
positive and relapses were seen after a median time of 36 
months (range 36-60). Overall, the 7 relapsing patients 
were re-treated with RTX (again as monotherapy) after a 
median of 54 months (36-96). Six months after treatment 
for relapse, 6 of 7 patients (86%) were in complete 
remission, while 1 (14%) patient with EGPA experienced 
a minor relapse, requiring small doses of mycophenolate 
mofetil (MMF) as maintenance therapy at the dose of 
500 mg/day, which was withdrawn 7 months after RTX 
administration. Following re-treatment, they again showed 
complete remission over a median of 32 months (12-96) 
of observation after a second cycle of RTX. There were 
2 deaths (all due to cardiovascular causes - mean age of 
patients 79.2 years) after a median of 132 and 75 months 
after their first RTX cycle.
DISCUSSION
AAV, especially cANCA-related vasculitides, 
often presented with relapsing course. Relapse leads to 
increased immunosuppressive exposure and toxicity. 
Two randomized controlled trials have shown RTX to 
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be effective in inducing remission inpatients with newly 
diagnosed and relapsing disease. However, the optimal 
maintenance treatment is widely debated.
The “4 + 2” RTX protocol was used in the present 
study. This scheme was associated with a delayed 
occurrence of relapses with a complete discontinuation of 
steroids and immunosuppressive drugs [12]. This is the 
main interest of this protocol: the possibility to avoid the 
adverse effects related to the use of steroids and standard 
immunosuppressants, assuring a long-lasting remission. 
Besides, this scheme is also useful in low-compliant 
patients, and avoids hospitalization.
In a recent study, Alberici et al. [8] showed that 
relapses started to occur as early as 6 months after the last 
RTX infusion, but were more common between months 10 
and 24. In their study, the use of RTX given at 1 g every 
6 months for 24 months induced long-lasting remission of 
> 24 months in 50% of patients, while for the remaining 
RTX was able to keep the disease inactive while ongoing 
dosing is employed. At least in our hands, a single cycle 
of “4+2” Rituximab protocol was able to maintain a stable 
remission in more than 60% of the patients for at least 5 
years. 
When focusing on risk factors for relapses, several 
studies have shown that relapses are much more frequent 
in patients with PR3-AAV than in those with MPO-AAV, 
and PR3-ANCA positivity is often the most important 
risk factor for relapses in multivariate analyses [13-17]. 
A retrospective study found that the risk of relapse was 
particularly high if PR3-ANCAs persisting after induction 
therapy with cyclophosphamide [16], but this observation 
was not confirmed in a subsequent prospective study [17]. 
We observed that all 4 patients relapsing in the first 5 
years of follow-up after the first “4+2” Rituximab cycle 
were PR3 positive. In our study, probably due to the small 
sample size, no determinant other than PR3-positivity was 
found to be associated to a higher risk of relapse in the 
first 5 years. Whether serial measurements of ANCAs (as 
well as peripheral blood CD20+B-cells) could be used 
to guide the frequency of re-treatment with rituximab as 
opposed to fixed-interval re-dosing [18] is currently under 
investigation in a prospective trial (MAINRITSAN 2 
study) [19]. 
Due to the delayed onset of relapse, our experience 
suggests that the policy of monitoring patients could be 
better than to administer fixed doses of RTX whatever the 
clinical assessment, at least using our induction protocol. 
In brief, the novelty of this open single-center study 
relies on the extremely long-term follow-up and on the 
discontinuation of steroid- and immunosuppressive drugs 
following the 4+2 RTX protocol. These results confirm our 
observations in other immune-mediated diseases [20-23]. 
When compared to other regimen suggesting the use of 
RTX on a fixed scheme, our findings support the choice 
of a treatment-to-target approach to achieve an adequate 
degree of B-cell depletion and a clinical response in AAV. 
The efficacy of the 4+2 dose RTX protocol is probably 
related to a more effective tissue depleting activity when 
compared to the standard scheme, providing a more 
prolonged clinical remission. 
Figure 1: Relapse-free survival after rituximab (RTX) treatment stratified by MPO/PR3 positivity. 
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LIMITATIONS OF THE STUDY
The main limitations of our study are the open 
non-blinded nature and the limited number of enrolled 
subjects. However, those are counterbalanced by the facts 
that our data are supported by a very long term follow-
up in a cohort of real-life AAV patients and that “4+2 
RTX protocol” allows avoidance of standard maintenance 
immunosuppression and has a substantial steroid-sparing 
effect.
CONCLUSION
In one of longest follow up study (45-132 months), 
sustained clinical remission without immunosuppressive 
maintenance therapy (and a negligible dose of prednisone 
since the 3rdmonth) was obtained by a 4 + 2 infusion 
protocol of RTX in a selected sample of patients with 




Eleven patients with ANCA-associated vasculitis, 5 
women and 6 men, 5 with granulomatosis with polyangiitis 
(GPA), 4 with microscopic polyangiitis (MPA), and 2 with 
eosinophilic granulomatosis with polyangiitis (EGPA), 
mean age at the time of fist RTX cycle 67.5 years (range 
45-81), were deemed eligible for RTX therapy. Diagnosis 
of AAV was done according to the Chapel Hill Consensus 
Conference definitions [1] and reviewed according to 
the modified version [24]. Demographic data, clinical 
presentation and previous treatments are described in 
details elsewhere [12].
In brief, 7 patients presented with renal involvement: 
6 had a biopsy-proven necrotizing extracapillary 
paucimmune glomerulonephritis, 1 case did not undergo 
renal biopsy because of concomitant anti-coagulation 
therapy due to the presence of antiphospholipid antibodies. 
Sinus involvement and lung nodules were detected in 5 
cases, retro-orbital granulomata in 2 patients. Biopsy-
proven leukocytoclastic vasculitis and large necrotizing 
skin ulcers were present in 2 cases. Polyneuropathy was 
observed in 7 patients, while arthralgia and weakness 
were found in 9 cases, and fever in 6. Six patients (3 
GPA 2 MPA and 1 EGPA) were found to be resistant to 
cyclophosphamide (CYC). One more GPA patient was in 
a relapsing phase albeit an elevated cumulative dose of 
CYC. Another GPA patient had a history of severe CYC-
induced leukopenia when addressed to our centre from 
another hospital because of a life-threatening disease. A 
MPA patient could not be treated with CYC because of 
a sudden pancytopenia after 1 week of oral treatment at 
the conventional dose (2 mg/kg). One MPA and 1 EGPA 
CYC-naive patient refused to accept the risks of infertility 
related to CYC treatment. 
Protocol
RTX was administered intravenously at a dose of 
375 mg/m 2 on days 1, 8, 15 and 22. Two more doses were 
administered 1 and 2 months after the last administration 
[23]. 
Response to treatment
Response was evaluated by assessing the changes 
in clinical signs and symptoms and laboratory parameters. 
Major relapse was defined as reappearance or worsening 
of disease as measured with an increase of at least 1 point 
of BVAS when compared to the score value obtained 
after previous treatment and involvement of at least one 
Table 1: Clinical and laboratory parameters before and after the “4+2” Rituximab protocol
Baseline (mean value±SD) 3 months 1 year 3 year End of follow-up
CRP
(mg/dl) 7.2±3.1 2.1±2.5 0.5±1.1 0.8±1.0 0.4±1.2
ESR
mm/h 56 ±46 21±18 18±11 16±7 11±5
ANCA
(UI/l) 25±15 12±7 5±6 9±7 5±6
Proteinuria
(g/24h) 1.2±0.6 0.47±0.4 0.26±0.4 0.40±0.4 0.21±0.3
IgG
(mg/dl) 976±123 715±65 698±87 701±57 681±98
IgM
(mg/dl) 147±76 95±41 89±23 75±65 68±43
BVAS (mean) 22 4 3 0 0
ANCA, anti-neutrophil cytoplasmic antibodies (cut-off 10 IU/l); CRP, C-reactive protein.
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major organ. Minor relapse was defined as worsening of 
disease with mild clinical symptoms associated with re-
appearance of ANCA together with CD20 repopulation. 
The Birmingham Vasculitis Activity Score (BVAS) 
was calculated at study entry, monthly for the first 6 
months and every six month during the follow-up or in 
case of relapse [25].
Statistical analysis
For comparison of variables at baseline and 
follow-up, Student’s t-test was used for continuous and 
Fisher’s test for categorical variables, as appropriate. 
Correlations were calculated and significance determined 
by. Multivariable logistic regression analysis was used 
to identify any independent predictors of AAV relapse. 
Kaplan-Meier hazard plots were constructed for time 
to time to AAV relapse. For these analyses, SPSS (IBM 
Corporation, NY, USA) software program was used. p < 
0.05 was considered significant.
This study was performed according to the local 
rules of off-label therapy in Piedmont Region (Northwest 
Italy).
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